Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYN | P07948 | 1/20 | 0.72 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.63 |
| ▸ | BRAF | P15056 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13797958 | 0.92 | LYN (0.72) | LYNMAPK9MAPK14BRAF | |
| SCHEMBL13797953 | 0.91 | LYN (0.71) | LYNMAPK9MAPK14BRAF | |
| SCHEMBL13797952 | 0.90 | MAPK14 (0.72) | LYNMAPK9MAPK14BRAFALDH1A1 | |
| SCHEMBL13798003 | 0.90 | LYN (0.78) | LYNMAPK9MAPK14BRAF | |
| SCHEMBL13797967 | 0.90 | LYN (0.69) | LYNMAPK9MAPK14BRAF | |
| SCHEMBL13797956 | 0.90 | LYN (0.69) | LYNMAPK9MAPK14BRAF | |
| SCHEMBL13797944 | 0.88 | LYN (0.67) | LYNMAPK9MAPK14BRAFSMN1; SMN2 | |
| SCHEMBL13798007 | 0.88 | LYN (0.71) | LYNMAPK9MAPK14BRAF | |
| SCHEMBL3252708 | 0.88 | LYN (0.67) | LYNMAPK9MAPK14BRAF | |
| SCHEMBL3258067 | 0.87 | LYN (0.77) | LYNMAPK9MAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497278-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-1497278-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1497278-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087085-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | IL6, IL1A, IL1B | LYN 2917/4885MAPK9 1942/4885MAPK14 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.